Galcanezumab

加卡奈珠单抗

Report date: 2024/01/10 16:04:23

Base Information

Drug NameGalcanezumab
Drug Alias NameCGRP antibody for prevention of migraine伽奈珠单抗加卡奈组单抗galcanezumabumGalcanezumab-gnlm +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCalcitonin gene-related peptide antagonists
TargetsCalcitonin gene-related peptide
Therapy Area/IndicationsCluster HeadacheMigraine DisordersAlzheimer Disease +[4] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/27
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesXuanwu Hospital Of Capital Medical UniversityArteaus Therapeutics LLCEli Lilly And Company +[6] 
Inactive CompaniesUniversity Of California San FranciscoAffamed Therapeutics Ltd
Active IndicationsCluster HeadacheMigraine DisordersAlzheimer Disease
Inactive IndicationsOsteoarthritis, Knee

Other Information

ATC CodeN02CD02
Related LinksWikipediaDrugBankKEGG